Company Performance - Tidewater reported quarterly earnings of $1.23 per share, significantly exceeding the Zacks Consensus Estimate of $0.28 per share, representing an earnings surprise of +339.29% [1] - The company posted revenues of $341.43 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.50% and showing a slight increase from $339.23 million in the same quarter last year [2] - Over the last four quarters, Tidewater has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Future Outlook - The sustainability of Tidewater's stock price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.20 on revenues of $350.07 million, and for the current fiscal year, it is $3.14 on revenues of $1.34 billion [7] - The estimate revisions trend for Tidewater was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Oil and Gas - Integrated - United States industry, to which Tidewater belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Tidewater's stock performance [5]

Core Insights - Encompass Health (EHC) reported quarterly earnings of $1.4 per share, exceeding the Zacks Consensus Estimate of $1.2 per share, and showing an increase from $1.11 per share a year ago, resulting in an earnings surprise of +16.67% [1] - The company achieved revenues of $1.46 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.29% and up from $1.3 billion year-over-year [2] - Encompass Health has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the previous quarter was +15.13%, with actual earnings of $1.37 per share compared to an expected $1.19 per share [1] - The current consensus EPS estimate for the upcoming quarter is $1.16 on revenues of $1.47 billion, and for the current fiscal year, it is $5.01 on revenues of $5.89 billion [7] Stock Performance and Outlook - Encompass Health shares have increased approximately 17.5% since the beginning of the year, outperforming the S&P 500's gain of 6.1% [3] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] Industry Context - Encompass Health operates within the Medical - Outpatient and Home Healthcare industry, which is currently ranked in the top 26% of over 250 Zacks industries [8] - The industry’s strong performance is supported by empirical research showing that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

Company Performance - CVRx reported a quarterly loss of $0.57 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.52, but an improvement from a loss of $0.65 per share a year ago, indicating a -9.62% earnings surprise [1] - The company posted revenues of $13.59 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.96% and showing an increase from $11.81 million in the same quarter last year [2] - Over the last four quarters, CVRx has surpassed consensus revenue estimates four times, but has only done so for EPS estimates once [2] Stock Performance - CVRx shares have declined approximately 40.3% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.47 on revenues of $14.54 million, and for the current fiscal year, it is -$1.97 on revenues of $56.54 million [7] Industry Outlook - The Medical - Instruments industry, to which CVRx belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of CVRx's stock may be influenced by the overall outlook of the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - ZoomInfo reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.23 per share, and up from $0.17 per share a year ago, representing an earnings surprise of +8.70% [1] - The company posted revenues of $306.7 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.37%, compared to year-ago revenues of $291.5 million [2] - Over the last four quarters, ZoomInfo has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - The immediate price movement of ZoomInfo's stock will largely depend on management's commentary during the earnings call, as the stock has underperformed the market with a loss of about 2.9% since the beginning of the year [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.25 on revenues of $297.86 million, and for the current fiscal year, it is $0.97 on revenues of $1.2 billion [7] Industry Context - The Internet - Software industry, to which ZoomInfo belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Group 1 - BioCryst Pharmaceuticals reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, compared to a loss of $0.06 per share a year ago, representing an earnings surprise of +400.00% [1] - The company posted revenues of $163.35 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 9.74%, and compared to year-ago revenues of $109.33 million [2] - BioCryst has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with BioCryst shares gaining about 5.7% since the beginning of the year, compared to the S&P 500's gain of 6.1% [3] - The current consensus EPS estimate for the coming quarter is $0.06 on revenues of $155.49 million, and $0.13 on revenues of $609.2 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 32% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Idexx Laboratories (IDXX) came out with quarterly earnings of $3.63 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.44 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +9.67%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.92 per share when it actually produced earnings of $2.96, delivering a surprise of +1.37%. Ov ...

Group 1 - Piper Sandler Companies reported quarterly earnings of $2.95 per share, exceeding the Zacks Consensus Estimate of $1.99 per share, and showing an increase from $2.52 per share a year ago, resulting in an earnings surprise of +48.24% [1] - The company achieved revenues of $405.39 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 17.61%, compared to $339.18 million in the same quarter last year [2] - Piper Sandler Companies has outperformed consensus EPS estimates in all four of the last quarters [2] Group 2 - The stock has increased approximately 5.1% since the beginning of the year, while the S&P 500 has gained 7.8% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.92 on revenues of $406.9 million, and for the current fiscal year, it is $12.75 on revenues of $1.6 billion [7] Group 3 - The Financial - Investment Bank industry, to which Piper Sandler belongs, is currently ranked in the top 7% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Piper Sandler was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Company Performance - EchoStar reported a quarterly loss of $1.06 per share, which was better than the Zacks Consensus Estimate of a loss of $1.12, but worse than a loss of $0.76 per share a year ago [1] - The company achieved an earnings surprise of +5.36% for the quarter, having previously reported a loss of $0.71 per share against an expectation of $0.9 per share, resulting in a surprise of +21.11% [2] - Revenues for the quarter were $3.72 billion, missing the Zacks Consensus Estimate by 2.87%, and down from $3.95 billion year-over-year [3] Stock Performance - EchoStar shares have increased by approximately 42.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.8% [4] - The current consensus EPS estimate for the upcoming quarter is -$1.29 on revenues of $3.82 billion, and for the current fiscal year, it is -$4.30 on revenues of $15.4 billion [8] Industry Outlook - The Satellite and Communication industry, to which EchoStar belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, indicating potential challenges ahead [9] - Telesat, another company in the same industry, is expected to report a quarterly loss of $0.69 per share, reflecting a year-over-year change of +76%, with revenues anticipated to be $79.05 million, down 29.1% from the previous year [10][11]

分组1 - Ares Management reported quarterly earnings of $1.03 per share, missing the Zacks Consensus Estimate of $1.11 per share, but showing an increase from $0.99 per share a year ago, resulting in an earnings surprise of -7.21% [1] - The company posted revenues of $1.05 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.41%, and compared to year-ago revenues of $786.5 million [2] - Ares Management shares have increased approximately 4.8% since the beginning of the year, while the S&P 500 has gained 7.8% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $1.14 on revenues of $1.08 billion, and for the current fiscal year, it is $5.12 on revenues of $4.78 billion [7] - The Zacks Industry Rank for Financial - Investment Management is currently in the top 19% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - BrightSpring Health Services, Inc. (BTSG) reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.19 per share, and showing a significant increase from $0.10 per share a year ago, resulting in an earnings surprise of +15.79% [1] - The company achieved revenues of $3.15 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.40%, and up from $2.73 billion in the same quarter last year [2] - BrightSpring Health Services has outperformed the S&P 500, with shares increasing approximately 21.3% since the beginning of the year compared to the S&P 500's gain of 7.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.28 on revenues of $3.16 billion, and for the current fiscal year, it is $0.90 on revenues of $12.29 billion [7] - The estimate revisions trend for BrightSpring Health Services was favorable ahead of the earnings release, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which BrightSpring belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]